Zentalis Pharmaceuticals (ZNTL) Equity Ratio (2022 - 2025)
Historic Equity Ratio for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to 0.77.
- Zentalis Pharmaceuticals' Equity Ratio fell 172.0% to 0.77 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.77, marking a year-over-year decrease of 172.0%. This contributed to the annual value of 0.78 for FY2024, which is 117.1% down from last year.
- Per Zentalis Pharmaceuticals' latest filing, its Equity Ratio stood at 0.77 for Q3 2025, which was down 172.0% from 0.78 recorded in Q2 2025.
- In the past 5 years, Zentalis Pharmaceuticals' Equity Ratio registered a high of 0.84 during Q2 2023, and its lowest value of 0.77 during Q1 2025.
- Moreover, its 4-year median value for Equity Ratio was 0.79 (2023), whereas its average is 0.8.
- Over the last 5 years, Zentalis Pharmaceuticals' Equity Ratio had its largest YoY gain of 441.66% in 2024, and its largest YoY loss of 759.25% in 2024.
- Zentalis Pharmaceuticals' Equity Ratio (Quarter) stood at 0.8 in 2022, then fell by 1.49% to 0.79 in 2023, then fell by 1.17% to 0.78 in 2024, then dropped by 1.38% to 0.77 in 2025.
- Its Equity Ratio was 0.77 in Q3 2025, compared to 0.78 in Q2 2025 and 0.77 in Q1 2025.